0
Abstract: Slide Presentations |

Nosocomial Respiratory Pathogens: Trends in Antibiotic Resistance, 1995-2003. Results of the Antimicrobial Resistance Management (ARM) Program FREE TO VIEW

John G. Gums, PharmD*
Author and Funding Information

University of Florida, Gainesville, FL


Chest


Chest. 2004;126(4_MeetingAbstracts):717S. doi:10.1378/chest.126.4_MeetingAbstracts.717S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa are among the primary bacterial etiologic pathogens identified in nosocomial respiratory tract infections. The ARM Program (www.armprogram.com) is an ongoing project to document trends in antimicrobial susceptibility patterns and identify relationships between antibiotic use and resistance rates.

METHODS:  Antibiograms/sensitivity reports from 1995-2003 (1997 for levofloxacin and cefepime) were analyzed from the ARM surveillance database, which contains susceptibility results on 24.1 million inpatient/outpatient isolates (19 organisms/48 antibiotics) collected from 314 US institutions. S pneumoniae isolates were reviewed for resistance to penicillin, cefuroxime, ceftriaxone, and levofloxacin; H influenzae to ampicillin and ceftriaxone; K pneumoniae to cefotaxime, ceftriaxone, cefepime, ciprofloxacin, and levofloxacin; and P aeruginosa to ceftazidime, cefepime, ciprofloxacin, levofloxacin, gentamicin, tobramycin, and imipenem.

RESULTS:  Between 1995-2003, S pneumoniae resistance to penicillin increased 6.5% and to levofloxacin, 1.9%; resistance decreased 14.9% to cefuroxime and 27.9% to ceftriaxone. For H influenzae, resistance to ampicillin increased 11.6% and to ceftriaxone, 1.3%. For K pneumoniae, resistance to cefotaxime increased 5.4%; to ceftriaxone, 3.6%; cefepime, 3.6%; ciprofloxacin, 3.4%; levofloxacin 3.3%. P aeruginosa resistance to ceftazidime increased 16.2%; to cefepime, 1.4%; ciprofloxacin, 15.5%; levofloxacin, 2.3%; gentamicin, 16.1%; tobramycin, 10.2%; and imipenem, 10.7%.

CONCLUSION:  The prevalence of resistance among nosocomial pathogens to commonly prescribed antibiotics increased between 1995 and 1998, with the exception of S pneumoniae to ceftriaxone and cefuroxime, which both showed a decline in resistance.

CLINICAL IMPLICATIONS:  Use of ARM Program data enables institutions to delineate occurrence and extent of antimicrobial resistance, allowing strategic intervention and the potential to reduce costs of antibiotics associated with inappropriate use.

DISCLOSURE:  J.G. Gums, Aventis Pharmaceuticals, Wyeth Pharmaceuticals, Roche Pharmaceuticals, Pfizer Pharmaceuticals

Monday, October 25, 2004

10:30 AM- 12:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543